Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$8.2 - $12.4 $118,506 - $179,204
-14,452 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$11.8 - $18.2 $87,320 - $134,680
-7,400 Reduced 33.86%
14,452 $17,000
Q1 2021

May 17, 2021

BUY
$15.2 - $25.0 $332,150 - $546,300
21,852 New
21,852 $35,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $13M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.